Circulating tumor DNA-guided minimal residual disease assessment in colorectal cancer

Pharmacogenomics. 2023 Jan;24(1):1-4. doi: 10.2217/pgs-2022-0170. Epub 2023 Jan 17.

Authors

Sakti Chakrabarti¹, Amit Mahipal¹

Affiliation

¹ Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA.

PMID: 36648355
DOI: 10.2217/pgs-2022-0170

No abstract available

Keywords: adjuvant; colorectal cancer; ctDNA; minimal residual disease.

Publication types

Editorial

MeSH terms

Biomarkers, Tumor
Circulating Tumor DNA* / genetics
Colorectal Neoplasms* / diagnosis
Colorectal Neoplasms* / genetics
Colorectal Neoplasms* / pathology
Humans
Neoplasm Recurrence, Local
Neoplasm, Residual / genetics

Substances

Circulating Tumor DNA
Biomarkers, Tumor